Developing an oncolytic Newcastle disease virus production process with EB66 cells.
Saved in:
| Title: | Developing an oncolytic Newcastle disease virus production process with EB66 cells. |
|---|---|
| Authors: | Jacobtorweihe, Lennart1 (AUTHOR), Saulnier, Annabelle2 (AUTHOR), Léon, Arnaud2 (AUTHOR), Genzel, Yvonne1 (AUTHOR) genzel@mpi-magdeburg.mpg.de, Reichl, Udo1,3 (AUTHOR) |
| Source: | Applied Microbiology & Biotechnology. 6/4/2026, Vol. 110 Issue 1, p1-14. 14p. |
| Subjects: | Newcastle disease virus, Cell lines, Cell culture, Oncolytic virotherapy, Cancer treatment, Bioreactors, Tumor growth |
| Abstract: | Newcastle disease virus (NDV) has been the subject of extensive research as a potential oncolytic virus for various types of cancer. While clinical studies are ongoing, the manufacturing of high NDV doses on a large scale is challenging. It has previously been documented that Vero cells are capable of producing 2.4 × 108 TCID50/mL in suspension batch production. However, the requirement of higher input doses and the challenging nature of establishing high cell density processes with Vero cells are significant obstacles in the effective utilization of these therapies. In pursuit of enhanced process intensification and the generation of viral vectors at elevated cell densities, EB66 cells have been identified as a highly effective producer cell line. In this study, the characteristics of EB66 cells in regard to NDV production were examined, with particular reference to cell growth and cell-specific virus productivity in batch and semi-perfusion mode. Optimal infection conditions for producing NDV in batch and semi-perfusion modes were identified for cultivation parameters including temperature, protease concentration (TrypLE), and multiplicity of infection. The favorable production conditions were then transferred to different batch processes using a stirred tank bioreactor and an orbital shaken bioreactor. These processes yielded up to 4.2 × 108 TCID50/mL of the NDV LaSota strain with a cell-specific virus yield of 41 TCID50/cell. First semi-perfusion runs resulted in concentrations of 65 × 106 cells/mL and an infectious virus titer of 7.5 × 108 TCID50/mL. Finally, the potency of the produced viruses was evaluated, and a reduction in tumor size in mice after NDV injection was demonstrated. Overall, these results indicate that EB66 cells could be a viable host for producing oncolytic NDV. [ABSTRACT FROM AUTHOR] |
| Copyright of Applied Microbiology & Biotechnology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Newcastle disease virus (NDV) has been the subject of extensive research as a potential oncolytic virus for various types of cancer. While clinical studies are ongoing, the manufacturing of high NDV doses on a large scale is challenging. It has previously been documented that Vero cells are capable of producing 2.4 × 108 TCID50/mL in suspension batch production. However, the requirement of higher input doses and the challenging nature of establishing high cell density processes with Vero cells are significant obstacles in the effective utilization of these therapies. In pursuit of enhanced process intensification and the generation of viral vectors at elevated cell densities, EB66 cells have been identified as a highly effective producer cell line. In this study, the characteristics of EB66 cells in regard to NDV production were examined, with particular reference to cell growth and cell-specific virus productivity in batch and semi-perfusion mode. Optimal infection conditions for producing NDV in batch and semi-perfusion modes were identified for cultivation parameters including temperature, protease concentration (TrypLE), and multiplicity of infection. The favorable production conditions were then transferred to different batch processes using a stirred tank bioreactor and an orbital shaken bioreactor. These processes yielded up to 4.2 × 108 TCID50/mL of the NDV LaSota strain with a cell-specific virus yield of 41 TCID50/cell. First semi-perfusion runs resulted in concentrations of 65 × 106 cells/mL and an infectious virus titer of 7.5 × 108 TCID50/mL. Finally, the potency of the produced viruses was evaluated, and a reduction in tumor size in mice after NDV injection was demonstrated. Overall, these results indicate that EB66 cells could be a viable host for producing oncolytic NDV. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 01757598 |
| DOI: | 10.1007/s00253-026-13889-9 |
